ArrowMark Colorado Holdings’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-16,100
| Closed | -$32K | – | 312 |
|
|
2024
Q3 | $32K | Hold |
16,100
| – | – | ﹤0.01% | 300 |
|
|
2024
Q2 | $56.4K | Hold |
16,100
| – | – | ﹤0.01% | 310 |
|
|
2024
Q1 | $44.6K | Hold |
16,100
| – | – | ﹤0.01% | 316 |
|
|
2023
Q4 | $27.4K | Sell |
16,100
-2,189
| -12% | -$2.41K | ﹤0.01% | 307 |
|
|
2023
Q3 | $18.8K | Sell |
18,289
-8,084
| -31% | -$11.5K | ﹤0.01% | 306 |
|
|
2023
Q2 | $30.6K | Sell |
26,373
-3,310,941
| -99% | -$5.9M | ﹤0.01% | 301 |
|
|
2023
Q1 | $5.04M | Sell |
3,337,314
-223,534
| -6% | -$560K | 0.06% | 198 |
|
|
2022
Q4 | $8.9M | Sell |
3,560,848
-2,040,259
| -36% | -$6.57M | 0.11% | 159 |
|
|
2022
Q3 | $23.6M | Sell |
5,601,107
-1,048,065
| -16% | -$4.1M | 0.29% | 93 |
|
|
2022
Q2 | $18.6M | Buy |
6,649,172
+62,670
| +1% | +$252K | 0.21% | 107 |
|
|
2022
Q1 | $37.7M | Buy |
6,586,502
+180,637
| +3% | +$1.32M | 0.33% | 89 |
|
|
2021
Q4 | $58.5M | Sell |
6,405,865
-15,470
| -0.2% | -$158K | 0.47% | 68 |
|
|
2021
Q3 | $68.6M | Buy |
6,421,335
+517,367
| +9% | +$6.3M | 0.54% | 57 |
|
|
2021
Q2 | $91.6M | Buy |
5,903,968
+272,952
| +5% | +$4.34M | 0.69% | 47 |
|
|
2021
Q1 | $91.3M | Buy |
5,631,016
+269,405
| +5% | +$4.8M | 0.68% | 45 |
|
|
2020
Q4 | $113M | Buy |
5,361,611
+302,085
| +6% | +$5.25M | 0.88% | 41 |
|
|
2020
Q3 | $75M | Sell |
5,059,526
-111,898
| -2% | -$1.75M | 0.71% | 47 |
|
|
2020
Q2 | $76.1M | Buy |
5,171,424
+736,637
| +17% | +$12.1M | 0.79% | 39 |
|
|
2020
Q1 | $52.1M | Buy |
4,434,787
+326,159
| +8% | +$6.13M | 0.68% | 49 |
|
|
2019
Q4 | $96.6M | Sell |
4,108,628
-58,622
| -1% | -$1.3M | 0.86% | 40 |
|
|
2019
Q3 | $77.1M | Buy |
4,167,250
+260,888
| +7% | +$4.8M | 0.77% | 46 |
|
|
2019
Q2 | $72.6M | Buy |
3,906,362
+1,237,719
| +46% | +$24.7M | 0.7% | 52 |
|
|
2019
Q1 | $65.2M | Buy |
2,668,643
+443,593
| +20% | +$11.6M | 0.61% | 57 |
|
|
2018
Q4 | $57.7M | Buy |
2,225,050
+198,909
| +10% | +$5.47M | 0.61% | 58 |
|
|
2018
Q3 | $64.1M | Sell |
2,026,141
-192,235
| -9% | -$7.16M | 0.54% | 62 |
|
|
2018
Q2 | $86.2M | Sell |
2,218,376
-149,546
| -6% | -$4.76M | 0.79% | 41 |
|
|
2018
Q1 | $65.4M | Buy |
2,367,922
+1,529,805
| +183% | +$34.7M | 0.65% | 58 |
|
|
2017
Q4 | $15.2M | Buy |
838,117
+208,548
| +33% | +$3.4M | 0.15% | 135 |
|
|
2017
Q3 | $10.2M | Buy |
629,569
+79,609
| +14% | +$1.25M | 0.12% | 161 |
|
|
2017
Q2 | $7.62M | Buy |
549,960
+29,791
| +6% | +$431K | 0.09% | 177 |
|
|
2017
Q1 | $7.8M | Buy |
+520,169
| New | +$7.2M | 0.11% | 150 |
|
|
2016
Q4 | – | Sell |
-2,232
| Closed | -$38K | – | 364 |
|
|
2016
Q3 | $38K | Buy |
+2,232
| New | +$41.4K | ﹤0.01% | 307 |
|
Other funds holding HRTX
RCMNY
VCIM
TC
PCM
ArrowMark Colorado Holdings's HRTX Position: Q4 2024 in Review
ArrowMark Colorado Holdings sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 16,100 shares — an estimated $32K sold.
ArrowMark Colorado Holdings first reported a position in HRTX in Q3 2016 and held it in 32 quarters. The position peaked at $113M in Q4 2020. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.
- ArrowMark Colorado Holdings reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
- ArrowMark Colorado Holdings sold 16,100 Heron Therapeutics shares in Q4 2024, an estimated $32K.
- ArrowMark Colorado Holdings first reported a position in Heron Therapeutics in Q3 2016 and held it in 32 quarters.
- ArrowMark Colorado Holdings's Heron Therapeutics position peaked at $113M in Q4 2020.
- 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.
Based on ArrowMark Colorado Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.